A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT03866382

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-25T22:29:04.642791+00:00

Published At

2026-04-22T00:00:00+00:00

Record Updated At

2026-04-22

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Bladder Adenocarcinoma", "Bladder Clear Cell Adenocarcinoma", "Bladder Mixed Adenocarcinoma", "Bladder Neuroendocrine Carcinoma", "Bladder Small Cell Neuroendocrine Carcinoma", "Bladder Squamous Cell Carcinoma", "Chromophobe Renal Cell Carcinoma", "Collecting Duct Carcinoma", "Invasive Bladder Giant Cell Urothelial Carcinoma", "Invasive Bladder Lymphoepithelioma-Like Carcinoma", "Invasive Bladder Nested Urothelial Carcinoma", "Invasive Bladder Plasmacytoid Urothelial Carcinoma", "Invasive Bladder Sarcomatoid Urothelial Carcinoma", "Invasive Bladder Urothelial Carcinoma", "Kidney Medullary Carcinoma", "Large Cell Neuroendocrine Carcinoma", "Malignant Testicular Leydig Cell Tumor", "Malignant Testicular Sertoli Cell Tumor", "Metastatic Bladder Carcinoma", "Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma", "Metastatic Bladder Giant Cell Urothelial Carcinoma", "Metastatic Bladder Large Cell Neuroendocrine Carcinoma", "Metastatic Bladder Lipid-Rich Urothelial Carcinoma", "Metastatic Bladder Micropapillary Urothelial Carcinoma", "Metastatic Bladder Plasmacytoid Urothelial Carcinoma", "Metastatic Bladder Sarcomatoid Urothelial Carcinoma", "Metastatic Bladder Small Cell Neuroendocrine Carcinoma", "Metastatic Bladder Squamous Cell Carcinoma", "Metastatic Chromophobe Renal Cell Carcinoma", "Metastatic Kidney Medullary Carcinoma", "Metastatic Malignant Genitourinary System Neoplasm", "Metastatic Papillary Renal Cell Carcinoma", "Metastatic Penile Carcinoma", "Metastatic Prostate Small Cell Neuroendocrine Carcinoma", "Metastatic Sarcomatoid Renal Cell Carcinoma", "Metastatic Urethral Carcinoma", "Papillary Renal Cell Carcinoma", "Sarcomatoid Renal Cell Carcinoma", "Stage IV Bladder Cancer AJCC v8", "Stage IV Penile Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IV Urethral Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8", "Urachal Adenocarcinoma", "Urethral Clear Cell Adenocarcinoma"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2026-04-22"

protocolSection.identificationModule.nctId

"NCT03866382"

protocolSection.identificationModule.officialTitle

"A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Bladder Adenocarcinoma (protocolSection.conditionsModule.conditions)
• Bladder Clear Cell Adenocarcinoma (protocolSection.conditionsModule.conditions)
• Bladder Mixed Adenocarcinoma (protocolSection.conditionsModule.conditions)
• Bladder Neuroendocrine Carcinoma (protocolSection.conditionsModule.conditions)
• Bladder Small Cell Neuroendocrine Carcinoma (protocolSection.conditionsModule.conditions)
• Bladder Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
• Chromophobe Renal Cell Carcinoma (protocolSection.conditionsModule.conditions)
• Collecting Duct Carcinoma (protocolSection.conditionsModule.conditions)
• Invasive Bladder Giant Cell Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
• Invasive Bladder Lymphoepithelioma-Like Carcinoma (protocolSection.conditionsModule.conditions)
• Invasive Bladder Nested Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
• Invasive Bladder Plasmacytoid Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
• Invasive Bladder Sarcomatoid Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
• Invasive Bladder Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
• Kidney Medullary Carcinoma (protocolSection.conditionsModule.conditions)
• Large Cell Neuroendocrine Carcinoma (protocolSection.conditionsModule.conditions)
• Malignant Testicular Leydig Cell Tumor (protocolSection.conditionsModule.conditions)
• Malignant Testicular Sertoli Cell Tumor (protocolSection.conditionsModule.conditions)
• Metastatic Bladder Carcinoma (protocolSection.conditionsModule.conditions)
• Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
• Metastatic Bladder Giant Cell Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
• Metastatic Bladder Large Cell Neuroendocrine Carcinoma (protocolSection.conditionsModule.conditions)
• Metastatic Bladder Lipid-Rich Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
• Metastatic Bladder Micropapillary Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
• Metastatic Bladder Plasmacytoid Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
• Metastatic Bladder Sarcomatoid Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
• Metastatic Bladder Small Cell Neuroendocrine Carcinoma (protocolSection.conditionsModule.conditions)
• Metastatic Bladder Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
• Metastatic Chromophobe Renal Cell Carcinoma (protocolSection.conditionsModule.conditions)
• Metastatic Kidney Medullary Carcinoma (protocolSection.conditionsModule.conditions)
• Metastatic Malignant Genitourinary System Neoplasm (protocolSection.conditionsModule.conditions)
• Metastatic Papillary Renal Cell Carcinoma (protocolSection.conditionsModule.conditions)
• Metastatic Penile Carcinoma (protocolSection.conditionsModule.conditions)
• Metastatic Prostate Small Cell Neuroendocrine Carcinoma (protocolSection.conditionsModule.conditions)
• Metastatic Sarcomatoid Renal Cell Carcinoma (protocolSection.conditionsModule.conditions)
• Metastatic Urethral Carcinoma (protocolSection.conditionsModule.conditions)
• Papillary Renal Cell Carcinoma (protocolSection.conditionsModule.conditions)
• Sarcomatoid Renal Cell Carcinoma (protocolSection.conditionsModule.conditions)
• Stage IV Bladder Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
• Stage IV Penile Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
• Stage IV Renal Cell Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
• Stage IV Urethral Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
• Stage IVB Prostate Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
• Urachal Adenocarcinoma (protocolSection.conditionsModule.conditions)
• Urethral Clear Cell Adenocarcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.